Coherus Biosciences Inc (CHRS) was Initiated by Citigroup to “Buy” and the brokerage firm has set the Price Target at $36. Citigroup advised their investors in a research report released on Jul 27, 2016.
Coherus Biosciences Inc closed down -1.21 points or -4.69% at $24.57 with 2,60,226 shares getting traded on Thursday. Post opening the session at $26.15, the shares hit an intraday low of $24.42 and an intraday high of $26.269 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.
In a different news, on Jul 25, 2016, Peter K. Watler (Chief Technical Officer) sold 3,991 shares at $26.27 per share price. According to the SEC, on Jul 5, 2016, Alan C. Herman (Chief Scientific Officer) sold 4,250 shares at $16.89 per share price. On May 26, 2016, Mats Wahlstrom (director) sold 6,372 shares at $33.50 per share price, according to the Form-4 filing with the securities and exchange commission.
Coherus BioSciences Inc. is a late-stage clinical biologics platform company focused on the global biosimilar market. The Company’s clinical-stage pipeline consists of two anti-inflammatory agents targeting tumor necrosis factor (TNF) and a long-acting form of granulocyte colony-stimulating factor (G-CSF). The Company’s product pipeline includes anti-TNF product candidate CHS-0214 an etanercept (Enbrel) biosimilar candidate which is in Phase III clinical trials and anti-TNF product candidate CHS-1420 an adalimumab (Humira) biosimilar candidate which is in Phase III clinical trials. The Company also offers G-CSF product candidate CHS-1701 a pegfilgrastim (Neulasta) biosimilar which has completed a Phase I study.